296 RASolve 301 Trial in Progress: A Phase 3 Study of Daraxonrasib (RMC-6236) vs. Docetaxel in Patients with Previously Treated RAS-Mutant Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer 2026

View at publisher
Authors: Colin R. Lindsay, Ferdinandos Skoulidis, Kathryn Cecilia Arbour, Hidehito Hironouchi, Gérard Zalcman, Alessandra Curioni Fontecedro, Jarushka Naidoo, Adrianus Johannes de Langen, Lin Tao, Erica Su, Minoti Hiremath, Achim Rittmeyer
+2 more Melissa Johnson, Sanjay Popat
DOI: 10.1016/j.lungcan.2026.109244
Cited by: 0

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Protein Kinase Regulation and GTPase Signaling Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
Lung Cancer
Volume
212
Pages
109244–109244
Publication date
1 February 2026
Language
EN